Darunavir: A critical review of its properties, use and drug interactions

Pharmacology

Volumn 90, Issue 1-2, 2012, Pages 102-109

  Ruela Corrêa, Josilene Chaves ^a   D'Arcy, Deirdre M ^c   Dos Reis Serra, Cristina Helena ^b   Nunes Salgado, Hérida Regina ^a  

^a SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

Acquired immune deficiency syndrome; Biopharmaceutics classification system; Clinical pharmacokinetics; Darunavir; Drug interactions; Human immunodeficiency virus

Indexed keywords

ATAZANAVIR PLUS RITONAVIR; ATORVASTATIN; CLARITHROMYCIN; DARUNAVIR; DARUNAVIR PLUS RITONAVIR; DIDANOSINE; EFAVIRENZ; ELVITEGRAVIR; ENFUVIRTIDE; ETHINYLESTRADIOL PLUS NORETHISTERONE; ETRAVIRINE; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; INDINAVIR; INDINAVIR PLUS RITONAVIR; KETOCONAZOLE; LOPINAVIR PLUS RITONAVIR; METHADONE; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; OMEPRAZOLE; ORAL CONTRACEPTIVE AGENT; PAROXETINE; PRAVASTATIN; RANITIDINE; RITONAVIR; RITONAVIR PLUS SAQUINAVIR; SERTRALINE; SILDENAFIL; TENOFOVIR; UNINDEXED DRUG;

ABDOMINAL PAIN; ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIVIRAL RESISTANCE; COMORBIDITY; DIARRHEA; DRUG BIOAVAILABILITY; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG METABOLISM; DRUG POTENCY; DRUG SAFETY; DRUG UTILIZATION; FOOD DRUG INTERACTION; GASTROINTESTINAL SYMPTOM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTRIGLYCERIDEMIA; LIFE EXPECTANCY; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NONHUMAN; OPPORTUNISTIC INFECTION; PATIENT COMPLIANCE; PHYSICAL CHEMISTRY; PLASMA CONCENTRATION-TIME CURVE; POLYPHARMACY; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RHINOPHARYNGITIS; TREATMENT OUTCOME; VOMITING;

DRUG INTERACTIONS; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; SULFONAMIDES;

EID: 84863760565     PISSN: 00317012     EISSN: 14230313     Source Type: Journal    
DOI: 10.1159/000339862     Document Type: Review

References (36)

1. Sharma P, Garg S: Pure drug and polymer based nanotechnologies for the improved solubility, stability, bioavailability and targeting of anti-HIV drugs. Adv Drug Deliv Rev 2010;62:491-502.
2. World Health Organization: AIDS epidemic update. 2009. http://www.who.int/mediacentre/news/releases/2009/hiv-aids-20091124/en/index. html (accessed August 2011).
3. Sasková KG, Kozísek M, Rezácová P, Brynda J, Yashina T, Kagan RM, Konvalinka J: Molecular characterization of clinical isolates of human immunodefciency virus resistant to the protease inhibitor darunavir. J Virol 2009;83:8810-8818.
4. Ghosh AK, Kincaid JF, Cho W, Walters DE, Krishnan K, Hussain KA, Koo Y, Cho H, Ru-dall C, Holland L, Buthod J: Potent HIV protease inhibitors incorporating high-affinity p2-ligands and (r)-(hydroxyethylamino)sul-fonamide isostere. Bioorg Med Chem Lett 1998;8:687-690.
5. Gyseghem E, Stokbroekx S, Armas HN, Dickens J, Vanstockem M, Baert L, Rosier J, Schueller L, Mooter G: Solid state characterization of the anti-HIV drug TMC114: interconversion of amorphous TMC114, TMC114 ethanolate and hydrate. Eur J Pharm Sci 2009;38:489-497.
6. Back D, Sekar VJ, Hoetelmans RM: Daruna-vir: pharmacokinetics and drug interactions. Antivir Ther 2008;13:1-13.
7. Food and Drug Administration: New labeling approved for Prezista (darunavir). 2010. http://www.fda.gov/ForConsumers/ByAudience/ ForPatientAdvocates/HIV andAIDSActivities/ucm236771.htm (accessed August 2011).
8. Nso-Roca A P, Larru B, Bellón JM, Mel-lado MJ, Ramos JT, González MI, Navarro ML, Muñoz-Fernández MA, José MI: Niveles plasmáticos de antirretrovirales en niños con infección por el virus de la inmunodefciencia humana. Infuencia del género y de la edad. Enferm Infecc Microbiol Clin 2010;28:278-283.
9. Sosnik A, Chiappetta DA, Carcaboso AM: Drug delivery systems in HIV pharmaco-therapy: what has been done and the challenges standing ahead. J Control Release 2009;138:2-15.
10. Food and Drug Administration: Pediatric focused safety review: darunavir ethano-late (Prezista). 2010. http://www.fda.gov/downloads/AdvisoryCommittees/ Commit-teesMeetingMaterials/PediatricAdvisoryCom-mittee/UCM235901.pdf (accessed August 2011).
11. New drugs. Drugs News 2009;34:125 (source: Medical News Today, February 12, 2009, www.prezista.com).
12. Curran A, Gutirerrez M, Deig E, Mateo G, Lopez RM, Imaz A, Crespo M, Ocaña I, Domingo P, Ribera E: Effcacy, safety and pharmacokinetics of 900/100 mg of daruna-vir/ritonavir once daily in treatment-experienced patients. J Antimicrob Chemother 2010;65:2195-2203.
13. Haubrich R, Berger D, Chiliade P, Colson A, Conant M, Gallant J, Wilkin T, Nadler J, Pierone G, Saag M, Baelen B, Lefebvre E: Week 24 efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients. Aids 2007;21:F11-F18.
14. Meyer S, Azijn H, Surleraux D, Jochmans D, Tahri A, Pauwels R, Wigerinck P, Bé-thune M-P: TMC114, a novel human immunodefciency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates. Antimicrob Agents Che-mother 2005;49:2314-2321.
15. Ripamonti D, Arribas J, Hill A, Pulido F, Moecklinghoff C, Nelson M: Non-inferior efficacy shown across different efficacy end-points in the MONET trial of darunavir/ritonavir (DRV/r) monotherapy. 12th European Aids Conference/EACS, Cologne, 2009, poster PS4/1.
16. Martindale: The Complete Drug Reference, ed 36. Philadelphia, Pharmaceutical Press, 2009.
17. TM, directions for use. 2008. www.accessdata.fda.gov/drugsatfda- docs/label/2008/021976s003s004lbl.pdf.
18. Tomaka F, Lefebvre E, Sekar V, Baelen B, Van-geneugden T, Vandevoorde A, Duvauchelle T, Miralles D: Similar changes in metabolic parameters of darunavir and atazanavir, each coadministered with low-dose ritona-vir in healthy volunteers (TMC114-C159). American Conference for the Treatment of HIV (ACTHIV), Dallas, 2007. http://www.ihlpress.com/pdf%20files/hivdart06-presentations/ Tomakapdf.pdf.
19. Fun A, Jong D, Nijhuis M: The genetic barrier of darunavir is decreased by Gag polymorphisms. 2011. 18th Conference on Retroviruses and Opportunistic Infections, Boston, 2011. http://www.retroconference.org/2011/PDFs/603.pdf.
20. Back D, Sekar V, Lefebvre E, Pauw M, Paepe E, Vangeneugden T, Hoetelmans R: Use of darunavir (TMC114) in combination with other drugs: guidance from pharmacokinetic studies. 8th International Congress on Drug Therapy in HIV Infection, Glasgow, 2006, poster PL5.1.
21. Sekar VJ, Guzman S, Stevens T, DePaepe E, Lefebvre E, Hoetelmans R: Absolute bioavail-ability of TMC114, administered in the absence and presence of low dose ritonavir. 7th International Workshop on Clinical Pharmacology of HIV Therapy, London, 2006, abstract 86.
22. Sekar VJ, Spinosa-Guzman S, Lefebvre E, Hoetelmans R: Clinical pharmacology of TMC114-a new HIV protease inhibitor. 16th International AIDS Conference, Toronto, 2006, poster TUPE 0083.
23. Sekar VJ, Kestens D, Spinosa-Guzman S, Pauw M, Paepe E, Vangeneugden T, Lefeb-vre E, Hoetelmans RM: The effect of different meal types on the pharmacokinetics of darunavir (TMC114)/ritonavir in HIV-neg-ative healthy volunteers. J Clin Pharmacol 2007;47:479-484.
24. Sekar VJ, Lefebvre E, Paepe E, Marez T, Pauw M, Parys W, Hoetelmans RM: Phar-macokinetic interaction between darunavir boosted with ritonavir and omeprazole or ranitidine in human immunodefciency virus-negative healthy volunteers. Antimicrob Agents Chemother 2007;51:958-961.
25. Sekar VJ, Abeele C V, Baelen B, Vis P, Lavreys L, Pauw M, Dincq S, Vangeneugden T, Spinosa-Guzman S, Hoetelmans R: Phar-macokinetic-pharmacodynamic analyses of once-daily darunavir in the ARTEMIS study. 9th International Workshop on Clinical Pharmacology of HIV Therapy, New Orleans, 2008, poster P42.
26. Sekar VJ, Lefebvre E, Pauw M, Vangeneug-den T, Hoetelmans RM: Pharmacokinetics of darunavir/ritonavir and ketoconazole following co-administration in HIV-healthy volunteers. Br J Pharmacol 2008;66: 215-221.
27. Sekar VJ, Spinosa-Guzman S, Paepe E, Pauw M, Vangeneugden T, Lefebvre E, Hoetel-mans RM: Darunavir/ritonavir pharmaco-kinetics following coadministration with clarithromycin in healthy volunteers. J Clin Pharmacol 2008;48:60-65.
28. Tomi M, Nishimura T, Nakashima E: Mother-to-fetus transfer of antiviral drugs and the involvement of transporters at the placental barrier. J Pharm Sci 2011;100:3708-3718.
29. Vermeir M, Lachau-Durand S, Mannens G, Cuyckens F, Hoof B, Raoof A: Absorption, metabolism, and excretion of darunavir, a new protease inhibitor, administered alone and with low-dose ritonavir in healthy subjects. Drug Metab Dispos 2009;37:809-820.
30. Rittweger M, Arastéh K: Clinical pharmaco-kinetics of darunavir. Clin Pharmacokinet 2007;46:739-756.
31. Sinha S, Ali M, Baboota S, Ahuja A, Kumar A, Ali J: Solid dispersion as an approach for bioavailability enhancement of poorly water-soluble drug ritonavir. AAPS J 2010;11: 518-527.
32. Amidon GL, Lennernas H, Shah V P, Crison JR: A theoretical basis for a biopharmaceu-tic drug classifcation: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 1995;12:413-420.
33. Dahan A, Miller JM, Amidon GL: Prediction of solubility and permeability class membership: provisional BCS classification of the world's top oral drugs. AAPS J 2009;11: 740-746.
34. European Medicines Agency: Pre-authori-zation evaluation of medicines for human use. Committee for Medicinal Products for Human Use. Guideline on the investigations of bioequivalence. 2008. http://www.ema. europa.eu/pdfs/human/ qwp/140198enrev1. pdf.
35. Food and Drug Administration: Guidance for industry: waiver of in vivo bioavailabil-ity and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system. 2000. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryIn-formation/ Guidances/ucm070246.pdf.
36. Fujimoto H, Higuchi M, Watanabe H, Koh Y, Ghosh AK, Mitsuya H, Tanoue N, Hamada A, Saito H: P-glycoprotein mediates effux transport of darunavir in human intestinal Caco-2 and ABCB1 gene-transfected renal LLC-PK1 cell lines. Biol Pharm Bull 2009; 32:1588-1593.